Literature DB >> 1317675

Case report: severe symptomatic hyponatremia associated with lisinopril therapy.

D Subramanian1, J C Ayus.   

Abstract

A 63-year-old white female who was being treated for hypertension with lisinopril presented with seizures, altered mental status, and a serum sodium of 101 mEq/L. Serum sodium prior to initiation of lisinopril therapy was 137 mEq/L. The hyponatremia was corrected and did not recur after lisinopril was stopped. The hyponatremia may have been a result of polydipsia and inappropriate antidiuresis secondary to ACE-inhibitor therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317675     DOI: 10.1097/00000441-199203000-00009

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  5 in total

Review 1.  [Aging and water metabolism in health and illness].

Authors:  M Miller
Journal:  Z Gerontol Geriatr       Date:  1999-07       Impact factor: 1.281

Review 2.  Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.

Authors:  K L Goa; J A Balfour; G Zuanetti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 3.  Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management.

Authors:  T Y Chan
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

Review 4.  Hyponatremia: pathophysiology, classification, manifestations and management.

Authors:  Helbert Rondon-Berrios; Emmanuel I Agaba; Antonios H Tzamaloukas
Journal:  Int Urol Nephrol       Date:  2014-09-24       Impact factor: 2.370

5.  Syndrome of inappropriate secretion of antidiuretic hormone associated with angiotensin-converting enzyme inhibitor therapy in the perioperative period.

Authors:  Takashin Nakayama; Hiroto Fujisaki; Shintaro Hirai; Ruri Kawauchi; Kyohei Ogawa; Ayaka Mitsui; Keita Hirano; Kazuo Isozumi; Takayuki Takahashi; Satoru Komatsumoto
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2019 Jan-Mar       Impact factor: 1.636

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.